25 / 38
Motzer R, et al. J Clin Oncol 2013
Tivozanib vs Sorafenib: Phase III trial
Overall
Age
Sex
Ethnicity
ECOG status
Time from diagnosis
to study entry
Prior systemic therapy
for metastatic disease
Geographic region
MSKCC risk score
< 65 years
≥
65 years
Female
Male
White
Nonwhite
0
1
< 1 year
≥
1 year
0
1
North America/Western Europe
Central/Eastern Europe
South America/Asia
Poor
Intermediate
Favorable
517
n
388
129
143
374
498
19
255
262
214
274
362
154
40
457
20
27
333
157
0 0.5 1 1.5 2 2.5 3
Tivozanib benefit Sorafenib benefit
Fig 3.
Forest plot: subgroup hazard ratios for
progression-free survival and their 95% CIs.
ECOG status, Eastern Cooperative Oncology
Group performance score; MSKCC, Memorial
Sloan-Kettering Cancer Center.
Tivozanib Versus Sorafenib as Initial Therapy for Metastatic RCC